Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.62 |
| ▸ | GLA | P06280 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | OGT | O15294 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10076159 | 0.88 | ALDH1A1 (0.52) | ALDH1A1GLAUSP2PKMHSD17B10 | |
| SCHEMBL10076150 | 0.87 | POLB (0.60) | ALDH1A1GLAUSP2PKMHSD17B10 | |
| SCHEMBL10076130 | 0.74 | ALDH1A1 (0.58) | ALDH1A1GLANPSR1POLBHTT | |
| SCHEMBL10076137 | 0.74 | ALDH1A1 (0.66) | ALDH1A1GLAHSD17B10NPSR1POLB | |
| SCHEMBL22500556 | 0.73 | TP53 (0.64) | ALDH1A1GLAUSP2PKMHSD17B10 | |
| SCHEMBL1911513 | 0.72 | ALDH1A1 (0.68) | ALDH1A1PKMNPSR1POLBLMNA | |
| SCHEMBL8660702 | 0.71 | F2 (0.58) | ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL16026437 | 0.71 | ALDH1A1 (0.83) | ALDH1A1PKMHSD17B10NPSR1POLB | |
| SCHEMBL28747190 | 0.70 | MMP2 (0.49) | ALDH1A1MAPK1 | |
| SCHEMBL10076154 | 0.70 | MMP2 (0.59) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093231-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | TELIK, INC. | 2008-02-14 | — | — | US | disclosed |
| US-7262182-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2007-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | MTAP, TYMP, PHOSPHO1 | ALDH1A1 4455/4885GLA 2364/4885USP2 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.